With partner Eli Lilly’s help, the radiopharmaceutical drugmaker priced one of the sector’s largest new stock offerings in the last two years.

In December, Vanity Fair published extensive interviews with Susie Wiles and other administration officials. Here are some ...

Richard Silverman, PhD, is a Northwestern University chemist whose name bears the building. His experimentation led to the ...

Members of a new class of antivirals are being tested in U.S. clinical trials, and one has gained approval in Japan, but how ...

Nanotechnology has revolutionized healthcare by enabling control over materials at the molecular and atomic level. Nanoscale materials exhibit unique ...

Immuneering Corporation stays a Strong Buy: pancreatic cancer combo shows 64% 12‑mo OS, strong safety, and clear catalysts ...

Using a blend of computer modeling, structural and cell-based studies, scientists at The Wertheim UF Scripps Institute have ...

Police said officers operated undercover in plain clothes inside retail stores, blending in with shoppers while monitoring ...

Pancreatic ductal adenocarcinoma (PDAC) is the most lethal form of pancreas cancer. It's also the most common form of the ...

The FDA and European Medicines Agency (EMA) have awarded orphan drug designation to CPI-008 (cRGD-ZW800-1), a novel ...

The financing, which will back a novel type of cancer drug, is the largest of a series of startup fundings announced at the ...

Zoldonrasib targets KRAS G12D-mutated non-small cell lung cancer, receiving FDA breakthrough therapy designation for its ...